师资队伍

导师队伍

首页 >> 师资队伍 >> 导师队伍 >> 正文

廖宇宁

发布日期:2023-03-15    作者:     来源:    点击:

个人概况

姓名 廖宇宁  性别:男

职称: 副研究员   导师资格:硕士生导师

单位:基础医学院

学历:博士研究生  毕业院校:广州医科大学

招生专业 病理学与病理生理学

电子邮件 liaoyuningm1@126.com

通信地址 广州市番禺区新造镇新造路1号广州医科大学番禺校区


研究方向

翻译后修饰与肿瘤


主持科研项目

1. 国家自然科学基金青年项目, 82002481, USP1-UAF1复合体调控RPS16的泛素化降解促进肝癌恶性进展,2021/01-2023/12,24万元,在研,主持;

2. 广州医科大学优青成长项目,蛋白质修饰与肿瘤,2023/01-2024/12,100 万元,在研,主持;

3. 广州市科技计划基础与应用基础研究项目, 202102020931, 去泛素化酶USP1调控肝癌细胞生长和侵袭转移的分子机制研究,2021/04-2023/03,5万元,在研,主持;

4. 广东省普通高校青年创新人才类项目, 2019KQNCX113, 核糖体蛋白降解调控在肝癌治疗中的作用及其分子机制研究,2020/01-2022/12,2.5万元,结题,主持;

5. 广州医科大学附属第六医院开放课题基金一般项目,202011-304,SIX1调控CDK1蛋白降解促进肝癌细胞的索拉菲尼抵抗,2021/01-2022/12, 20 万元,结题,主持


部分代表性第一和通讯作者论文

1. Liao Y#, Liu N#, Xia X, Guo Z, Li Y, Jiang L, Zhou R, Tang D, Huang H*, Liu J*. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discovery, 2019 Apr 30;5:24. (中科院1区,IF 38.079)

2. Liao Y#, Shao Z#, Liu Y#, Xia X, Deng Y, Yu C, Sun W, Kong W, He X, Liu F, Guo Z, Chen G, Tang D, Gan H*, Liu J*, Huang H*. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research, 2021 Jun 21;40(1):201. (中科院1区,IF 12.658)

3. Liao Y#, Liu Y#, Shao Z#, Xia X, Deng Y, Cai J, Yao L, He J, Yu C, Hu T, Sun W, Liu F, Tang D, Liu J*, Huang H*. A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. Oncogene, 2021 Jun 2. (中科院1区,IF 8.756)

4. Liao Y#, Liu Y#, Xia X#, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J*, Huang H*. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics, 2020 Feb 10; 10(8):3366-3381. (中科院1区,IF 11.6)

5. Liao Y#, Guo Z#, Xia X#, Liu Y, Huang C, Jiang L, Wang X, Liu J*, Huang H*. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. Journal of Experimental & Clinical Cancer Research, 2019 Apr 11;38(1):157. (中科院1区,IF 12.658)

6. Liao Y#, Xia X#, Liu N#, Cai J, Guo Z, Li Y, Jiang L, Dou Q, Tang D, Huang H*, Liu J*. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene, 2018 Apr;37(14):1896-1910. (中科院1区,IF 8.756)

7. Liao Y#, Liu N, Hua X, Cai J, Xia X, Wang X, Huang H*, Liu J*. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death & Disease, 2017 Feb 2;8(2):e2585. (中科院1区,IF 9.685)

8. Liao Y#, Sun W#, Shao Z#, Liu Y, Zhong X, Deng Y, Liu F, Huang H*, Liu J*. A SIX1 degradation inducer blocks excessive proliferation of prostate cancer. International Journal of Biological Sciences, 2022 Mar 14; 18(6): 2439-2451. (中科院2区,IF 10.75)

9. Liu Y#, Kong W#, Yu, C#, Shao Z, Lei Q, Deng Y, Cai G, Zhuang X, Sun W, Wu S, Wang R, Chen X, Chen G*, Huang H*, Liao Y*. SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. Acta Pharmacologica Sinica, 2022. (中科院1区,IF 7.169)

10. Liu Y#, Yu C#, Shao Z, Xia X, Hu T, Kong W, He X, Sun W, Deng Y, Liao Y*, Huang H*. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death Dis. 2021 Sep 21;12(10):857. (中科院1区,IF 9.685)